Cognitive Systems Launches Caregiver Aware, Enabling Service Providers to Enter the Remote Eldercare Industry
4.5.2022 14:50:00 EEST | Business Wire | Press release
Cognitive Systems Corp. announced today the launch of Caregiver Aware, a revolutionary advancement in preventative health. Working directly with service providers during development to understand their challenges, Caregiver Aware was designed with flexible go-to-market options that leverage providers’ existing infrastructure and hardware. Building on the success of its Home Aware security product that commercially launched in 2019, Caregiver Aware’s predictive analytics has the potential to significantly disrupt the broadband services market and our definition of “smart home.”
Caregiver Aware is powered by WiFi Motion™, which is currently active in over 70 countries and leverages connected IoT devices to transform the entire home into a motion-sensing network without additional hardware. It is an end-to-end solution featuring Cognitive Systems' patented algorithms, clean iOS and Android app interfaces. Backed by robust integration support from Cognitive’s QA and commercialization experts, the optimized data management system does not impact broadband performance. This launch represents a key moment for service providers looking to enter the rapidly growing field of remote eldercare by providing their customers with a tool for aging in place.
“Technology is accelerating the shift from reactive to proactive healthcare and we want to help lead that charge,” said Taj Manku, co-founder and CEO of Cognitive Systems. “Caregiver Aware has been on our product roadmap from the start, but the pandemic has made us all acutely aware of the need for innovation in preventative health. Our goal with this product is to create a bridge for service providers to build a care-focused ecosystem using data analytics, which will be a game-changing step in shaping future broadband services.”
Caregiver Aware is currently being trialed with service provider partners. It allows caregivers to complete remote wellness checks and view live motion in a loved one's home without intruding on their privacy or independence in the way cameras or wearable devices do. This launch represents the tip of the iceberg for remote eldercare monitoring, with new features already in development aimed at capturing behavioural patterns based on natural motion AI, improving localization and enabling customized notifications.
“As we worked towards a full-scale launch with more advanced features, user feedback confirmed immediate value in providing people with the peace of mind knowing a loved one is home, safe and active,” says Amanda Forsyth, Director of Product Management at Cognitive Systems. “This first iteration of Caregiver Aware is an important steppingstone towards a proactive health model and, with the majority of adults wanting to age in place, Caregiver Aware not only fills an industry need but a societal one.”
With aging populations around the world, the remote eldercare industry is poised to take off. However, with current world events and chip shortages, integration timelines can be lengthy. Service providers looking to enter the market need to start conversations now about where care solutions fit into their product roadmaps.
Learn more about how WiFi Sensing is ushering in a new era of preventative healthcare here.
About Cognitive Systems
Cognitive Systems Corp. is on a mission to transform the way WiFi networks are used. Its flagship technology, WiFi Motion™, uses wireless signals to sense motion in the home. WiFi Motion harnesses artificial intelligence and predictive analytics to reliably identify and localize motion for the smart home, home monitoring, and wellness monitoring markets. This patented technology is layered onto existing WiFi networks without additional hardware to enhance service provider and router manufacturer offerings.
www.cognitivesystems.com
https://www.linkedin.com/company/cognitive-systems-corp-/
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220504005187/en/
Contact information
Press
Proof Strategies
Jillian Colucci
jcolucci@getproof.com
416-801-9851
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Positive CHMP Opinion for Opzelura ® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 14:30:00 EEST | Press release
Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids (TCSs) and topical calcineurin inhibitors (TCIs) are inadequate or inappropriate. “AD is a chronic skin condition that can have a significant impact on daily life. The positive CHMP opinion for Opzelura marks meaningful progress toward bringing the first non-steroidal topical JAK treatment option to adults in Europe with moderate AD for whom standard topical therapies have failed,” said Lee Heeson, Executive Vice President and Head of Incyte International. “If approved by the European Commission, Opzelura could help address an important gap for patients who have limited treatment options when TCSs and TCIs are inadequate or inappropriate.” The positive CHMP o
Datroway ® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 14:00:00 EEST | Press release
Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the TROPION-Breast02phase 3 trial, which werepresented at the 2025 European Society for Medical Oncology Congress and published in Annals of Oncology. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In TROPION-Breast02, Datroway demonstrated a
DAYBU ® (trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 13:49:00 EEST | Press release
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating condition," said Catherine Owen Adams, Acadia’s Chief Executive Officer. “Our commitment is to make a meaningful difference in the lives of patients, caregivers, and the wider Rett com
HTEC Showcases Lakebase Branching at Databricks’ Data & AI Summit26.6.2026 12:18:00 EEST | Press release
HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. The Solution was developed in collaboration with a leading risk and compliance technology provider who serves financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626875859/en/ HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. Solving Critical Development Bottlenecks in Regulated Environments At the core of the collaboration was a shared challenge: how to enable modern data workflows in an envi
Stallergenes Greer Named One of Switzerland’s Best Managed Companies for 202626.6.2026 11:28:00 EEST | Press release
Stallergenes Greer, a global leader in allergy care, has been recognised for its overall business performance, company culture, and sustained growth by receiving the prestigious 2026 Switzerland’s Best Managed Companies award. The 2026 Best Managed Companies programme award winners are among Switzerland’s best private companies. The awards are derived from Deloitte’s global Best Managed Companies awards programme, an internationally recognised programme that evaluates businesses based on their leadership in the areas of strategy, culture and commitment, capabilities, innovation, governance and financial performance. Applicants are evaluated by an independent jury of experts. The evaluation of the Switzerland awards is based on more than 30 years of observed practice from the global awards programme that has been rolled out in 50+ countries worldwide. This recognition reflects Stallergenes Greer's consistent ability to deliver on its strategic vision while maintaining the operational di
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom